China launched three more space missions in recent weeks, debuting the country's first rocket to be fitted with strap-on solid-fueled boosters and deploying satellites to image planet Earth and calibrate orbit prediction models, according to Chinese state media.
The Government has taken several policy initiatives in the past few years and brought in reforms to encourage indigenous design, development and manufacture of defence equipment in the country. These initiatives, inter-alia, include according priority to procurement of capital items from domestic sources under Defence Acquisition Procedure (DAP)-2020; Announcement of 18 major defence platforms for […]
Next week, the House of Representatives plans to vote on a bill that would effectively decriminalize and deschedule cannabis, marking only the second time in over 50 years that a chamber of Congress has voted to reclassify cannabis from its existing status as a federally prohibited substance. What can we expect as far as timetables and anticipated […]
The creativity that surrounds the consumption of cannabis is astounding. Whilst some people are happy to simply roll up their bud in a joint or place it in a vaporizer, other people want more. Perhaps if cannabis had been legalized around the world earlier, then people wouldn’t have found so much joy in new and […]
Niantic has announced the full slate of five-star raids for Pokemon Go in April, and trainers should prepare to face off against the third Alolan island guardian starting April 12.
Tapu Bulu, the game's third Legendary Pokemon hailing from the Alolan region, has been named as the latest Pokemon Go five-star raid, running from now until April 26. Tapu Bulu's time as the five-star raid Pokemon was announced along with the Pokemon Go April 2022 event schedule, which runs concurrently with the game's Season of Alola event introducing Pokemon Sun and Moon to the game.
Tapu Bulu is the third "Tapu" Pokemon to be introduced to Pokemon Go, with Tapu Koko and Tapu Lele already in the game and only Tapu Fini still to come. If you caught Tapu Koko and Tapu Lele you're on your way to completing the set, so if you're going to challenge the Tapu Bulu raid check out our tips below.
Tapu Bulu will be the featured five-star raid April 12-26, with two special Raid Hours planned during that time.
Tapu Bulu Raid Schedule
Tapu Bulu enters the five-star Raid ring starting April 12 at 10 AM local time, remaining there until 8 PM on April 26. Unfortunately the game does not follow any set schedules with its raid--there's no guarantee Tapu Bulu will be waiting for you--but the game constantly tells you who's around to raid, so just keep an eye out.
There is a glimmer of hope for those who need a Tapu Bulu appearance though: Pokemon Go's weekly Raid Hour on Wednesday night. Two of April's Raid Hour events--April 13 and 20 from 6 PM to 7 PM local time--will feature the Land Spirit Pokemon at nearly every Gym in the game. If you want a guaranteed shot at Tapu Bulu, gather your friends and head out after dinner on those two Wednesday nights.
Tapu Bulu Weaknesses And Counters
Tapu Bulu is a Grass- and Fairy-type Pokemon, a rare type duo in the world of Pokemon shared only by four other Pokemon: Generation V's Cottonee and Whimsicott, and Generation VII's Morelull and Shiinotic. While Tapu Bulu's typing is hard to find elsewhere, its five weaknesses should make building a team to counter it much easier to pin down.
Poison-type Pokemon are Tapu Bulu's Poke-Kryptonite, with Poison-type moves seeing increased effectiveness against both Grass and Fairy Pokemon. As such, Weezing, Nidoking/Nidoqueen, Muk, and Gengar will be invaluable in a fight with this island deity.
Fire-, Flying-, Ice-, and Steel-type moves are also extra effective against Tapu Bulu, so any mixture of Skarmory, Charizard--perhaps the Mega Charizard Y you caught in the current Mega Raid--Ho-Oh, Articuno, or Alolan Ninetales will be helpful in the battle ahead.
Types To Avoid
The Grass- and Fairy-type Tapu Bulu is resistant to seven Pokemon types, nearly half of the 18 types featured in Pokemon games, so there are plenty of Pokemon to avoid. Dark-, Dragon-, Electric-, Fighting-, Grass-, Ground-, and Water-type Pokemon will all be battling from behind against Tapu Bulu, so leave traditionally powerful Pokemon like Blastoise, Dragonite, Lucario, Umbreon, and Absol behind when challenging the raid.
There's still some time before Tapu Bulu joins the five-star raid roster, so get yourself ready by catching as many Grass-types as you can during the current Lush Jungle event, or take on the current five-star raid Tapu Lele if you haven't done so already.
Bukele slams the US bill that targeted his Bitcoin law while the US Senators try to understand the effects that the bill has on the country but also on the US dollar so let’s read more in today’s latest Bitcoin news. The US lawmakers introduced a new bill to examine and to develop a plan […]
Everyone wants their weed these days, with all different ways to consume the plant. Some want to smoke it, some want to eat it in edibles, some only want to vape it, some take their bong hits, some rub it on their skin, some put oil under their tongue, and some swallow down tinctures or […]
This article was published as a part of the Data Science Blogathon. Dear readers, In this blog, we will get introduced to reinforcement learning and also implement a simple example of the same in Python. It will be a basic code to demonstrate the working of an RL algorithm. Brief exposure to object-oriented programming in Python, […]
HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.
Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas
Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.
-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively. -- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively. -- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively. -- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year. -- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively. -- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year. -- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.
Persistent R&D investment to develop and expand new specialty esoteric testing business lines
As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.
-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers. -- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy. -- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.
Entered the IVD reagents field and optimized immune repertoire deployment
Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.
As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.
Strategy and Prospects
The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.
Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."
About Kindstar Globalgene Technology, Inc. Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").